Amnon Peled - 20 Feb 2026 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Role
Director
Signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact
Issuer symbol
SLXN
Transactions as of
20 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 16:11:15 UTC
Previous filing
31 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Peled Amnon Director 55 NACHMANI ST, TEL AVIV, ISRAEL /s/ Mirit Horenshtein Hadar, Attorney-in-fact 23 Feb 2026 0002048879

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLXN Ordinary Shares Award $0 +7,576 +1146% $0.000000 8,237 20 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLXN Stock Option (right to buy Ordinary Shares) Award $0 +8,904 $0.000000 8,904 20 Feb 2026 Ordinary Shares 8,904 $1.65 Direct F2, F3
holding SLXN Stock Option (right to buy Ordinary Shares) 780 20 Feb 2026 Ordinary Shares 780 $18.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors.
F2 The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors.
F3 The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
F4 There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.